IGC Pharma, Inc.

IGC · AMEX
Analyze with AI
3/31/2025
3/31/2024
3/31/2023
3/31/2022
Operating Activities
Net Income-$7,121-$13,000-$11,506-$15,016
Dep. & Amort.$618$637$657$651
Deferred Tax$0$0-$451$0
Stock-Based Comp.$1,640$1,773$2,843$2,197
Change in WC-$72$1,894$794$2,536
Other Non-Cash$140$3,497$616$2,170
Operating Cash Flow-$4,795-$5,199-$7,047-$7,462
Investing Activities
PP&E Inv.-$112-$138-$619-$236
Net Acquisitions$0$0$538$0
Inv. Purchases$0$0-$154$0
Inv. Sales/Matur.$0$0-$538$0
Other Inv. Act.-$330-$179$538-$506
Investing Cash Flow-$442-$317-$235-$742
Financing Activities
Debt Repay.-$3-$3-$3-$3
Stock Issued$4,454$3,527$103$4,145
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$0
Financing Cash Flow$4,451$3,524$100$4,142
Forex Effect-$7-$6-$82-$26
Net Chg. in Cash-$793-$1,998-$7,264-$4,088
Supplemental Information
Beg. Cash$1,198$3,196$10,460$14,548
End Cash$405$1,198$3,196$10,460
Free Cash Flow-$5,277-$5,714-$7,666-$8,233
IGC Pharma, Inc. (IGC) Financial Statements & Key Stats | AlphaPilot